PainReform (PRFX) Competitors $1.34 -0.08 (-5.63%) Closing price 03:59 PM EasternExtended Trading$1.34 +0.00 (+0.37%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRFX vs. PHXM, IMCC, MBIO, ALBT, ERNA, APM, INAB, DWTX, ADXN, and KPRXShould you be buying PainReform stock or one of its competitors? The main competitors of PainReform include PHAXIAM Therapeutics (PHXM), IM Cannabis (IMCC), Mustang Bio (MBIO), Avalon GloboCare (ALBT), Ernexa Therapeutics (ERNA), Aptorum Group (APM), IN8bio (INAB), Dogwood Therapeutics (DWTX), Addex Therapeutics (ADXN), and Kiora Pharmaceuticals (KPRX). These companies are all part of the "pharmaceutical products" industry. PainReform vs. Its Competitors PHAXIAM Therapeutics IM Cannabis Mustang Bio Avalon GloboCare Ernexa Therapeutics Aptorum Group IN8bio Dogwood Therapeutics Addex Therapeutics Kiora Pharmaceuticals PHAXIAM Therapeutics (NASDAQ:PHXM) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation. Do analysts prefer PHXM or PRFX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00PainReform 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to PHXM or PRFX? In the previous week, PainReform had 2 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 2 mentions for PainReform and 0 mentions for PHAXIAM Therapeutics. PainReform's average media sentiment score of 0.45 beat PHAXIAM Therapeutics' score of 0.00 indicating that PainReform is being referred to more favorably in the news media. Company Overall Sentiment PHAXIAM Therapeutics Neutral PainReform Neutral Which has more volatility & risk, PHXM or PRFX? PHAXIAM Therapeutics has a beta of 2.35, suggesting that its stock price is 135% more volatile than the S&P 500. Comparatively, PainReform has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Do institutionals & insiders hold more shares of PHXM or PRFX? 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. Comparatively, 37.3% of PainReform shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Comparatively, 34.4% of PainReform shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is PHXM or PRFX more profitable? Company Net Margins Return on Equity Return on Assets PHAXIAM TherapeuticsN/A N/A N/A PainReform N/A N/A N/A Which has stronger earnings and valuation, PHXM or PRFX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPHAXIAM TherapeuticsN/AN/A-$240KN/AN/APainReformN/AN/A-$14.59M-$147.33-0.01 SummaryPainReform beats PHAXIAM Therapeutics on 5 of the 7 factors compared between the two stocks. Get PainReform News Delivered to You Automatically Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRFX vs. The Competition Export to ExcelMetricPainReformMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.86M$2.83B$5.75B$10.24BDividend YieldN/A56.54%5.69%4.60%P/E RatioN/A23.2874.9326.41Price / SalesN/A525.73452.3586.56Price / CashN/A27.5625.8129.91Price / Book0.645.4013.256.28Net Income-$14.59M$32.95M$3.29B$270.38M7 Day Performance-3.60%0.21%0.47%2.70%1 Month Performance-0.74%4.10%4.60%5.99%1 Year Performance-61.49%-2.91%73.42%25.94% PainReform Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRFXPainReform0.7524 of 5 stars$1.34-5.6%N/A-59.2%$2.86MN/A0.004Upcoming EarningsShort Interest ↑PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049IMCCIM Cannabis0.909 of 5 stars$1.90+2.7%N/A-14.0%$9.98M$39.44M-3.52340Positive NewsShort Interest ↓Gap DownMBIOMustang Bio1.0263 of 5 stars$1.36-0.4%N/A-88.3%$9.82MN/A-0.02100Positive NewsGap UpALBTAvalon GloboCare1.1135 of 5 stars$2.50+5.9%N/A-25.3%$9.60M$1.33M-0.135News CoverageAnalyst DowngradeShort Interest ↑ERNAErnexa Therapeutics0.9803 of 5 stars$1.23-0.5%N/A-94.3%$9.47M$580K-0.1510APMAptorum Group0.7651 of 5 stars$1.74+1.8%N/A-31.3%$9.31M$430K0.0030Short Interest ↑INABIN8bio3.491 of 5 stars$2.05-5.1%$180.00+8,680.5%-77.9%$9.31MN/A-0.2320Short Interest ↓DWTXDogwood Therapeutics2.1012 of 5 stars$4.83-1.4%$10.00+107.0%N/A$9.23MN/A-0.265Gap DownADXNAddex Therapeutics3.1794 of 5 stars$8.17+1.0%$30.00+267.2%+11.0%$9.22M$460K-25.5730Positive NewsGap DownKPRXKiora Pharmaceuticals2.6072 of 5 stars$2.66-1.3%$10.00+276.6%-27.9%$9.14M$16.02M-0.9210Short Interest ↑ Related Companies and Tools Related Companies PHXM Competitors IMCC Competitors MBIO Competitors ALBT Competitors ERNA Competitors APM Competitors INAB Competitors DWTX Competitors ADXN Competitors KPRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRFX) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PainReform With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRFX Stock Alerts